Citigroup Inc Iveric Bio, Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$26.24 - $39.63 $891,950 - $1.35 Million	33,992 Added 12.88%	297,957 $11.7 Million
Q1 2023 May 11, 2023	BUY	$18.67 - $24.56 $1.58 Million - $2.08 Million	84,617 Added 47.18%	263,965 $6.42 Million
Q4 2022 Feb 09, 2023	SELL	$17.24 - $23.95 $2.98 Million - $4.14 Million	-172,698 Reduced 49.06%	179,348 $3.84 Million
Q3 2022 Nov 10, 2022	SELL	$9.4 - $18.59 $87,946 - $173,928	-9,356 Reduced 2.59%	352,046 $6.32 Million
Q2 2022 Aug 10, 2022	BUY	$9.12 - $18.9 $2.71 Million - $5.63 Million	297,620 Added 466.62%	361,402 $3.48 Million
Q1 2022 May 12, 2022	SELL	$12.15 - $16.83 $2.88 Million - $3.99 Million	-236,927 Reduced 78.79%	63,782 $1.07 Million
Q4 2021 Feb 10, 2022	BUY	$13.83 - $18.78 $2.43 Million - $3.3 Million	175,692 Added 140.53%	300,709 $5.03 Million
Q3 2021 Nov 10, 2021	BUY	$7.07 - $17.5 $883,870 - $2.19 Million	125,017 New	125,017 $2.03 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.